RC-3095

• Description :

  RC-3095 is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2].

• UNSPSC :

  12352209

• Target :

  Bombesin Receptor

• Type :

  Peptides

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/rc-3095.html

• Solubility :

  H2O

• Smiles :

  O=C([C@H]1CC(C(C=CC=C2)=C2N3)=C3CN1)N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@H](C(N[C@@H](CC(C)C)CN[C@H](C(N)=O)CC(C)C)=O)CC4=CN=CN4)=O)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O

• Molecular Formula :

  C56H79N15O9

• Molecular Weight :

  1106.32

• References & Citations :

  [1]Oliveira PG, et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis Rheum. 2011 Oct;63 (10) :2956-65.|[2]Roesler R, et al. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol. 2004 Feb 13;486 (1) :35-41.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 2

• CAS Number :

  [138147-78-1]